Outcomes in Patients with Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers

Authors

• Timothy Voorhees, The Ohio State University Wexner Medical Center, Columbus, OH
• Eric McLaughlin, The Ohio State University, Columbus, OH
• Pallawi Torka, Memorial Sloan Kettering Cancer Center, New York, NY
• Jorge A. Florindez, University of North Carolina, Chapel Hill, NC
• Tamara K. Moyo, Atrium Health / Levine Cancer Institute, Charlotte, NC
• Heather Reves, University of Texas Southwestern, Dallas, TX
• Nuttavut Sumransub, University of Minnesota, Minneapolis, MN
• Saarang Deshpande, University of Pennsylvania, Philadelphia, PA
• Ashley Rose, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
• Cassandra Duarte, University of Colorado Cancer Center, Aurora, CO
• Muhammad Salman Faisal, Roswell Park Comprehensive Cancer Center, Buffalo, NY
• Showkat Hamid, Roswell Park Comprehensive Cancer Center, Buffalo, NY
• Suki Subbiah, LSU Health Sciences Center - New OrleansFollow
• Sabarish R. Ayyappan, University of Iowa, Iowa City, IA
• Lauren Kelly Shea, University of Alabama at Birmingham, Birmingham, AL
• Matthew J. Cortese, Roswell Park Comprehensive Cancer Center, Buffalo, NY
• Krish Patel, Swedish Cancer Institute, Seattle, WA
• Ajay Major, University of Colorado Cancer Center, Aurora, CO
• Hayder Saeed, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
• Jakub Svoboda, University of Pennsylvania, Philadelphia, PA
• Sanjal H. Desai, University of Minnesota, Minneapolis, MN
• Praveen Ramakrishnan Geethakumari, University of Texas Southwestern, Dallas, TX
• Natalie S. Grover, University of North Carolina, Chapel Hill, NC
• Narendranath Epperla, The Ohio State University Wexner Medical Center, Columbus, OH

Document Type

Conference Proceeding

Publication Date

11-2-2023

Publication Title

Blood

Abstract

Annual Conference of the Canadian Society of Clinical Chemists (CSCC), June 18-21, 2023, Winnipeg, Canada

First Page

3061

Volume

142

Issue

Supplement 1

Recommended Citation

Voorhees, Timothy; McLaughlin, Eric; Torka, Pallawi; Florindez, Jorge A.; Moyo, Tamara K.; Reves, Heather; Sumransub, Nuttavut; Deshpande, Saarang; Rose, Ashley; Duarte, Cassandra; Faisal, Muhammad Salman; Hamid, Showkat; Subbiah, Suki; Ayyappan, Sabarish R.; Shea, Lauren Kelly; Cortese, Matthew J.; Patel, Krish; Major, Ajay; Saeed, Hayder; Svoboda, Jakub; Desai, Sanjal H.; Ramakrishnan Geethakumari, Praveen; Grover, Natalie S.; and Epperla, Narendranath, "Outcomes in Patients with Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers" (2023). School of Medicine Faculty Publications. 4223.
https://digitalscholar.lsuhsc.edu/som_facpubs/4223
10.1182/blood-2023-181056